Clinical Trials Browser

INDUSTRY × Lymphoma, Non-Hodgkin × navitoclax × Clear all

Lymphoma, Non-Hodgkin, Leukemia, B-Cell, Hematologic Neoplasms

NCT00406809 2021-08-02

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies

DermatologicLymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, B-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Clinical Trials

Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers

A Study of ABT-263 in Subjects With Relapsed or Refractory Lymphoid Malignancies